Cue Biopharma, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cue Biopharma completed a $50M private placement financing and licensed CUE-221 (anti-IgE antibody for allergies) from Ascendant, paying ~$20M upfront plus $20M in warrant fair value. Q2 2026 net loss was $153.1M (largely non-cash: $90M warrant loss, $20M warrant fair value adjustment) versus $8.5M loss in Q2 2025. Cash post-PIPE rose from $17.4M (June 30) to $67.4M; stockholders' equity collapsed from $26.4M (Dec 2025) to $2.3M (June 2026) due to warrant liability accounting. Company appointed new CMO (Dr. Dominic Borie) and CFO (James Ahlers); expects CUE-221 Phase 2 data end-Q3 2026 and CUE-401 Phase 1 IND by year-end.
Why this rating
Massive $50M raise (96% of market cap) + pipeline acquisition are transformational for $52M company; however, large warrant liability and equity dilution weaken near-term balance sheet; clinical upside (IND submissions, Phase 2 data) and management reinforcement offset execution risk.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.